阿尔茨海默氏症疾病的神经病理学诊断的插图
Nicholas Doher1, Vahid Davoudi2, Shino Magaki3
1Department of Neurology, University of Florida, Gainesville, FL 32611, USA.
Neurology international
|July 25, 2023
概括
阿尔茨海默病 (AD) 诊断依赖于死后的神经病理学评估. 本概述阐明了国家阿尔茨海默氏症协调中心 (NACC) 评分方法,解决了在AD分期的潜在不准确性.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 生物标志物研究 生物标志物研究
背景情况:
- 阿尔茨海默病 (AD) 影响着数百万人,预计到2060年患病率将翻一番.
- 准确的神经病理学评估对于理解AD机制至关重要.
- 目前的死后诊断使用NACC编码指南,版本11.
研究的目的:
- 为提供对阿尔茨海默病死后诊断过程的简要概述.
- 为了突出ABC评分方法中的潜在模两可.
- 为了将死后发现与新出现的死前AD生物标志物联系起来.
主要方法:
- 审查国家阿尔茨海默氏症协调中心 (NACC) 编码指南,版本11.
- 对阿尔茨海默病神经病理变化的ABC评分方法的分析.
- 关于死后诊断和死前生物标志物之间的关系的讨论.
主要成果:
- 该NACC指南提供了目前用于死后AD分期的标准.
- 在ABC评分方法中的模两可可能会影响诊断的准确性和效率.
- 了解死后的变化有助于解释死前生物标记数据.
结论:
- 澄清死后诊断过程对于可靠的阿尔茨海默病病阶段确定至关重要.
- 解决ABC评分方法中的模两可,可以提高诊断准确度.
- 综合死后和死前数据可以提高我们对阿尔茨海默病进展的理解.
相关概念视频
01:26Alzheimer's Disease: Overview
524
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219